Approval · Notice of Compliance 37891 · 2026
RYBELSUS: Notice of Compliance 37891
Issued July 13, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37891
- Date
- July 13, 2026
- Company
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product Monograph update
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RYBELSUS | Not yet assigned | — |
Medicinal ingredients
- SEMAGLUTIDE 3 MG per TAB
- SEMAGLUTIDE 7 MG per TAB
- SEMAGLUTIDE 14 MG per TAB
- SEMAGLUTIDE 1.5 MG per TAB
- SEMAGLUTIDE 4 MG per TAB
- SEMAGLUTIDE 9 MG per TAB